Rulemaking

Effective October 19, 2026, Minnesota Rules, part 6800.3400, subpart 1a took effect and permits the following information to be included on prescription drug labels:

Subp. 1a. Additional labeling information. After January 1, 2026, except for radiopharmaceuticals, all drugs dispensed to or for a patient, other than an inpatient of a hospital, may also be labeled with the following information:

A. the complete and unabbreviated generic name of the drug; and
B. instructions written in plain language explaining the patient-specific indications for the drug if the patient-specific indications are indicated on the prescription.


Session Law:
The statutory authority to adopt these rules under the expedited rulemaking process is Minnesota Laws 2024, Regular Session, Chapter 127, Article 60, Section. 25.

  • Sec. 25. RULEMAKING; BOARD OF PHARMACY. The Board of Pharmacy must amend Minnesota Rules, part 6800.3400, to permit and promote the inclusion of the following on a prescription label: (1) the complete and unabbreviated generic name of the drug; and (2) instructions written in plain language explaining the patient-specific indications for the drug if the patient-specific indications are indicated on the prescription. The Board of Pharmacy must comply with Minnesota Statutes, section 14.389, in adopting the amendment to the rule.

Current rule:
Minnesota Rule 6800.3400

Subject matter:
Amendment to Rules Governing Prescription Bottle Labeling

Summary of changes:
Drugs dispensed to or for a patient, other than an inpatient of a hospital, may contain unabbreviated names of generic drugs, instructions in plain language explaining patient-specific indications for the drug if the patient-specific indications are indicated on the prescription.


Documents

Information about eComments is available on the Court of Administrative Hearings website.
If you have additional questions please contact the Board at pharmacy.board@state.mn.us using the subject Rulemaking.

Click this link to sign up for email updates from the Board of Pharmacy.